ArticleAnnals of clinical and translational neurology2026
Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Comparison With Rituximab.
Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), and compare it with rituximab.
methodsWe conducted a single-center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab. The primary outcome is relapse, while the secondary outcomes are disability status and adverse events.
resultsTwenty-two patients received ofatumumab for a median duration of 19.5 months (range 6-41). Among them, 18 patients (81.82%) remained relapse-free during follow-up. Annualized relapse rate (ARR) significantly decreased from 1.30 (95% CI 0.74-2.29) pretreatment to 0.12 (95% CI 0.04-0.35) during ofatumumab therapy (IRR 10.86, 95% CI 3.22-36.70, p < 0.001). Through propensity score matching, 11 patients in the ofatumumab group and 11 patients in the rituximab group were compared. Ofatumumab was observed to be associated with a significantly lower risk of a second attack (HR 0.233, 95% CI 0.061 to 0.893, p = 0.018) compared to rituximab. Adverse events were reported in 54.55% patients (6/11) treated with ofatumumab, most of which were mild and occurred after the initial dose.
interpretationOfatumumab was associated with a lower relapse risk compared with rituximab in patients with MOGAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.